A Multicenter, Phase 1B, Open-Label Study To Determine The Safety And Activity Of CC-292 In Combination With Lenalidomide In Subjects With Relapsed And/Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ID Number 13-1824Principal Investigator(s)
Janice L. Gabrilove
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to determine the side effects of a new experimental drug called CC 292 taken together with a drug called lenalidomide which is approved for other diseases. “Experimental” means that the study drugs are currently being tested and are not approved by the Food and Drug Administration (FDA) to treat CLL/SLL. This study will test the safety of this combination and to see if it helps patients with CLL or SLL. This study will also help to find the best dose of these drugs to use in future studies.
This study also includes testing of blood and optional lymph node samples for biomarkers. Biomarkers are substances such as proteins and genes that tell us how the study drugs are working in your body. In this study, biomarkers in your blood or lymph node sample will be measured to see if and how the chemical makeup of your blood or lymph node sample plays a role in how you respond or do not respond to the study drugs.
Recruiting Patients: Yes